Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | PKLR | P30613 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244741 | 0.99 | AKR1C3 (0.67) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| SCHEMBL5243114 | 0.99 | AKR1C3 (0.67) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| SCHEMBL5243117 | 0.99 | AKR1C3 (0.67) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| Benzamide SCHEMBL27708563 | 0.91 | AKR1C3 (0.58) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| SCHEMBL27708599 | 0.90 | AKR1C3 (0.57) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| SCHEMBL5243753 | 0.86 | HSD11B1 (0.72) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| SCHEMBL27708604 | 0.86 | AKR1C3 (0.53) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| Lithium Ion SCHEMBL1712866 | 0.86 | AKR1C3 (0.55) | AKR1C3AKR1C1PKLRPOLBFAAH | |
| SCHEMBL5243320 | 0.85 | POLB (0.63) | AKR1C3AKR1C1TSHRL3MBTL1PKLR | |
| SCHEMBL5243329 | 0.85 | POLB (0.63) | AKR1C3AKR1C1TSHRL3MBTL1PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | KNUST HENNER (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202888-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2252587-B1 | PIPERIDINE SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| EP-2252587-A1 | PIPERIDINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009100994-A1 | PIPERIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | WO | disclosed |
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | AKR1C3 1634/4885AKR1C1 1264/4885TSHR 733/4885 |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | AKR1C3 1634/4885AKR1C1 1264/4885TSHR 733/4885 |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | AKR1C3 1634/4885AKR1C1 1264/4885TSHR 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.